Citation: Da. Fischer et Jh. Toogood, THE PUBLICATION PATTERN OF PHARMACEUTICAL COMPANY SPONSORED TRIALS OFANTIASTHMATIC INHALED CORTICOSTEROID EQUIVALENCY AND EFFICACY, Journal of allergy and clinical immunology, 101(1), 1998, pp. 280-280
Citation: Jh. Toogood et Jc. Baskerville, THERAPEUTIC EFFICIENCY OF HIGH-DOSE BUDESONIDE (BUD) FOR ASTHMA - A BENEFIT RISK ANALYSIS/, Journal of allergy and clinical immunology, 101(1), 1998, pp. 282-282
Citation: J. Vanschoor et al., DIFFERENTIAL-EFFECTS OF INHALED BUDESONIDE AND ORAL PREDNISOLONE ON SERUM IMMUNOGLOBULIN-G AND ITS SUBCLASSES IN HEALTHY ADULT VOLUNTEERS, Clinical and experimental allergy, 27(2), 1997, pp. 192-195
Authors:
TOOGOOD JH
WHITE FA
BASKERVILLE JC
FRAHER LJ
JENNINGS B
Citation: Jh. Toogood et al., COMPARISON OF THE ANTIASTHMATIC, OROPHARYNGEAL, AND SYSTEMIC GLUCOCORTICOID EFFECTS OF BUDESONIDE ADMINISTERED THROUGH A PRESSURIZED AEROSOL PLUS SPACER OR THE TURBUHALER DRY POWDER INHALER, Journal of allergy and clinical immunology, 99(2), 1997, pp. 186-193
Authors:
TOOGOOD JH
WHITE F
ANDERSON J
BASKERVILLE J
Citation: Jh. Toogood et al., OROPHARYNGEAL COMPLICATIONS OF BUDESONIDE (BUD) INHALATION VIA THE TURBUHALER (TBH) OR PRESSURIZED METERED-DOSE AEROSOL WITH NEBUHALER (NEB) SPACER, Journal of allergy and clinical immunology, 99(1), 1997, pp. 1332-1332
Citation: Jh. Toogood et al., COMPARING THE SAFETY OF GENERIC (GEN) VERSUS STANDARD (STD) ANTIASTHMATIC INHALED STEROIDS (I-S), Journal of allergy and clinical immunology, 99(1), 1997, pp. 1340-1340
Authors:
DALES RE
SCHWEITZER I
TOOGOOD JH
DROUIN M
YANG W
DOLOVICH J
BOULET J
Citation: Re. Dales et al., RESPIRATORY-INFECTIONS AND THE AUTUMN INCREASE IN ASTHMA MORBIDITY, The European respiratory journal, 9(1), 1996, pp. 72-77
Citation: Jh. Toogood et al., A METHODOLOGICAL ASSESSMENT OF DIURNAL VARIABILITY OF PEAK FLOW AS A BASIS FOR COMPARING DIFFERENT INHALED STEROID FORMULATIONS, Journal of allergy and clinical immunology, 98(3), 1996, pp. 555-562
Authors:
TOOGOOD JH
FRAHER LJ
CHENG S
BASKERVILLE J
Citation: Jh. Toogood et al., SERUM OSTEOCALCIN (SO) AND PROCOLLAGEN (PICP) AS MARKERS FOR OSTEOPOROTIC FRACTURE RISK IN STEROID-DEPENDENT ASTHMATICS, Journal of allergy and clinical immunology, 97(1), 1996, pp. 686-686
Citation: J. Vanschoor et al., SHORT COURSES OF HIGH-DOSE INHALED BUDESONIDE AND SERUM IGG SUBCLASS LEVELS IN HEALTHY-VOLUNTEERS, Journal of allergy and clinical immunology, 97(1), 1996, pp. 113-118
Authors:
TOOGOOD JH
BASKERVILLE JC
MARKOV AE
HODSMAN AB
FRAHER LJ
JENNINGS B
HADDAD RG
DROST D
Citation: Jh. Toogood et al., BONE-MINERAL DENSITY AND THE RISK OF FRACTURE IN PATIENTS RECEIVING LONG-TERM INHALED STEROID-THERAPY FOR ASTHMA, Journal of allergy and clinical immunology, 96(2), 1995, pp. 157-166
Citation: J. Baskerville et al., RELIABILITY OF DIURNAL VARIABILITY OF PEAK FLOW (DVPF) FOR COMPARING INHALED STEROID FORMULATIONS, Journal of allergy and clinical immunology, 95(1), 1995, pp. 310-310
Authors:
WHITE FA
TOOGOOD JH
BASKERVILLE J
HODSMAN A
Citation: Fa. White et al., A COMPARISON OF THE EFFICACY AND SYSTEMIC EFFECTS OF BUDESONIDE (BUD)ADMINISTERED AS AN AEROSOL VIA METERED-DOSE INHALER (MDI) PLUS NEBUHALER AND AS A DRY POWDER VIA TURBUHALER (TBH), Journal of allergy and clinical immunology, 95(1), 1995, pp. 312-312
Authors:
TOOGOOD JH
BASKERVILLE J
HODSMAN A
FRAHER L
MARKOV A
Citation: Jh. Toogood et al., EFFECTS OF LONG-TERM INHALED STEROID (I-S) AND ORAL STEROID (O-S) THERAPY ON BONE-MINERAL DENSITY (BMD) IN ASTHMATIC ADULTS, Journal of allergy and clinical immunology, 93(1), 1994, pp. 200-200
Authors:
MILLER MA
GREENBERGER PA
AMERIAN R
TOOGOOD JH
NOSKIN GA
ROBERTS M
PATTERSON R
Citation: Ma. Miller et al., ALLERGIC BRONCHOPULMONARY MYCOSIS CAUSED BY PSEUDALLESCHERIA-BOYDII, The American review of respiratory disease, 148(3), 1993, pp. 810-812